These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39159595)

  • 21. Cutaneous metastasis from urologic tumors.
    Kumar P; Prasad N; Biswas G; Parikh PM
    Indian J Dermatol Venereol Leprol; 2006; 72(1):86. PubMed ID: 16481729
    [No Abstract]   [Full Text] [Related]  

  • 22. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced or metastatic urothelial cell carcinoma (JASINT-1 - AB 38/11) of AUO].
    Rexer H
    Urologe A; 2011 Aug; 50(8):974-6. PubMed ID: 21779884
    [No Abstract]   [Full Text] [Related]  

  • 24. [Sensitivity tests of anti-cancer drugs with human tumor stem cell assay. 2. The results in renal cell carcinoma and urothelial carcinoma].
    Sakuramoto T; Miura T; Kubota Y
    Nihon Hinyokika Gakkai Zasshi; 1985 May; 76(5):645-8. PubMed ID: 4057715
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 26. [Metastatic transitional cell carcinoma with high CA 19.9 serum levels].
    Camain JY; Hammel P; Cazals-Hatem D; Levy P; Belghiti J; Ruszniewski P
    Gastroenterol Clin Biol; 2007 Jan; 31(1):102-5. PubMed ID: 17273142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avelumab for the treatment of urothelial cancer.
    Rodriguez-Vida A; Bellmunt J
    Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatments for patients with progressive metastatic urothelial carcinoma.
    Rosenberg JE
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):180-183. PubMed ID: 33739967
    [No Abstract]   [Full Text] [Related]  

  • 29. [Synchronous renal carcinoma and urothelioma of the contralateral renal pelvis].
    Ronchetti E; Fava G; Dossena G; Rolandi P; Lo Re V; Fibbi ML
    Minerva Chir; 1999 May; 54(5):359-62. PubMed ID: 10443118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Update 2016 - Immunotherapy for urothelial carcinoma].
    Retz M; Gschwend JE; Schmid SC
    Urologe A; 2016 Feb; 55(2):246-52. PubMed ID: 26767648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
    Thalmann GN; Markwalder R; Walter B; Studer UE
    J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic factors in renal tumors of urothelial origin].
    Salinas Sánchez AS; Moreno Avilés J; Tomás Ros M; Martínez Pertusa P; Server Falgas G
    Arch Esp Urol; 1988 Jun; 41(5):335-9. PubMed ID: 3190271
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.
    Bracarda S; Altavilla A; Hamzaj A; Sisani M; Marrocolo F; Del Buono S; Danielli R
    Semin Oncol; 2015 Jun; 42(3):495-505. PubMed ID: 25965369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?
    Jaime-Casas S; Yip W; Jeter JM
    JCO Precis Oncol; 2024 Jul; 8():e2400324. PubMed ID: 39088771
    [No Abstract]   [Full Text] [Related]  

  • 39. Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers.
    Apolo AB; Msaouel P; Niglio S; Simon N; Chandran E; Maskens D; Perez G; Ballman KV; Weinstock C
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35609225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary treatment of metastatic renal cell carcinoma.
    Wiechno P; Kucharz J; Sadowska M; Michalski W; Sikora-Kupis B; Jonska-Gmyrek J; Poniatowska G; Nietupski K; Ossolinski K; Demkow T
    Med Oncol; 2018 Oct; 35(12):156. PubMed ID: 30368624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.